David Boyer W.'s Insider Trades & SAST Disclosures
David Boyer W.'s most recent trade in Neurocrine Biosciences, Inc. was a trade of 34,153 Stock Option done . Disclosure was reported to the exchange on Feb. 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Boyer W..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 34,153 | 34,153 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,401 | 6,401 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,811 | 3,623 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,811 | 3,809 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,541 | 4,624 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,541 | 4,395 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 116.79 per share. | 12 Feb 2025 | 955 | 2,854 (0%) | 0% | 116.8 | 111,538 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 116.69 per share. | 12 Feb 2025 | 830 | 3,565 (0%) | 0% | 116.7 | 96,849 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,329 | 2,698 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,329 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 118.31 per share. | 08 Feb 2025 | 700 | 1,998 (0%) | 0% | 118.3 | 82,820 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,096 | 2,473 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,096 | 2,096 | - | - | Restriced Stock Unit | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 152.94 per share. | 31 Jan 2025 | 1,104 | 1,369 (0%) | 0% | 152.9 | 168,849 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 113.66 per share. | 03 Oct 2024 | 1,295 | 377 (0%) | 0% | 113.7 | 147,190 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 121.88 per share. | 13 Sep 2024 | 3,461 | 1,672 (0%) | 0% | 121.9 | 421,828 | Common Stock |
| Neurocrine Biosciences, Inc. | David Boyer W. | Chief Corp. Affairs Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 30,977 | 30,977 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Boyer W. David | Chief Corp. Affairs Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 6,165 | 6,165 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | W. David Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 133.10 per share. | 13 Feb 2024 | 955 | 5,751 (0%) | 0% | 133.1 | 127,106 | Common Stock |
| Neurocrine Biosciences, Inc. | W. David Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 133.05 per share. | 13 Feb 2024 | 856 | 4,895 (0%) | 0% | 133.0 | 113,889 | Common Stock |
| Neurocrine Biosciences, Inc. | W. David Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 134.19 per share. | 06 Feb 2024 | 700 | 5,523 (0%) | 0% | 134.2 | 93,932 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 136.78 per share. | 06 Feb 2024 | 628 | 4,895 (0%) | 0% | 136.8 | 85,898 | Common Stock |
| Neurocrine Biosciences, Inc. | Boyer David W. | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 141.96 per share. | 06 Feb 2024 | 240 | 5,110 (0%) | 0% | 142.0 | 34,070 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 141.96 per share. | 06 Feb 2024 | 216 | 4,894 (0%) | 0% | 142.0 | 30,663 | Common Stock |
| Neurocrine Biosciences, Inc. | W. David Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 140.87 per share. | 31 Jan 2024 | 1,104 | 5,886 (0%) | 0% | 140.9 | 155,524 | Common Stock |
| Neurocrine Biosciences, Inc. | Boyer W. David | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 140.72 per share. | 31 Jan 2024 | 992 | 4,894 (0%) | 0% | 140.7 | 139,591 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 107.41 per share. | 21 Aug 2023 | 1,600 | 6,193 (0%) | 0% | 107.4 | 171,862 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 45,027 | 45,027 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 7,245 | 7,245 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 102.41 per share. | 06 Feb 2023 | 12,801 | 15,624 (0%) | 0% | 102.4 | 1,310,985 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 102.42 per share. | 06 Feb 2023 | 11,497 | 4,127 (0%) | 0% | 102.4 | 1,177,534 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 104.11 per share. | 06 Feb 2023 | 700 | 4,755 (0%) | 0% | 104.1 | 72,876 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 105.61 per share. | 06 Feb 2023 | 240 | 4,127 (0%) | 0% | 105.6 | 25,346 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 109.92 per share. | 31 Jan 2023 | 1,104 | 3,911 (0%) | 0% | 109.9 | 121,349 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 114.12 per share. | 31 Oct 2022 | 1,295 | 2,919 (0%) | 0% | 114.1 | 147,785 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 106.59 per share. | 03 Oct 2022 | 1,437 | 4,214 (0%) | 0% | 106.6 | 153,170 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 79.62 per share. | 07 Feb 2022 | 700 | 2,919 (0%) | 0% | 79.6 | 55,736 | Common Stock |
| Neurocrine Biosciences, Inc. | David W. Boyer | Chief Corp. Affairs Officer | Sale of securities on an exchange or to another person at price $ 81.07 per share. | 07 Feb 2022 | 240 | 2,291 (0%) | 0% | 81.1 | 19,457 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges